Gutron

Gutron is a prescription oral medication that contains the active ingredient midodrine hydrochloride. It is supplied in tablet form (strength not specified) and is marketed in the European Union. Midodrine is a pro‑drug that is converted in the body to desglymidodrine, an alpha‑1 adrenergic agonist that raises blood pressure by causing peripheral vasoconstriction. The drug belongs to the vasopressor/antihypotensive therapeutic class and is prescribed for patients with standing blood pressure.

Gutron is indicated for the treatment of orthostatic hypotension, a condition characterized by a significant drop in blood pressure upon standing.

- Improves symptoms such as dizziness, light‑headedness, and visual blur when moving to an upright position. - Helps maintain adequate cerebral perfusion in patients with chronic low‑standing blood pressure. - May be used as an adjunct to non‑pharmacologic measures (e.g., increased fluid intake, compression stockings). - Can be considered when other antihypotensive therapies are insufficient or not tolerated. - May be prescribed for patients whose orthostatic symptoms are not adequately controlled by lifestyle modifications alone.

The safety profile of Gutron includes both frequently observed and rare adverse reactions, which are generally dose‑related and reversible when the medication is stopped.

Common: - Headache, often mild and transient. - Piloerection (goose‑flesh) on the torso or limbs. - Scalp tingling, pruritus, or a feeling of coldness. - Urinary urgency or increased frequency, usually reversible. - Dry mouth or mild gastrointestinal discomfort.

Serious: - Supine hypertension: elevated blood pressure while lying down, which may require dose adjustment. - Severe bradycardia: markedly slowed heart rate that can cause dizziness. - Peripheral ischemia or necrosis (rare): reduced blood flow to extremities, potentially leading to tissue damage. - Allergic skin reactions such as rash or urticaria (rare).

When prescribing Gutron, clinicians should evaluate patient history and monitor for conditions that could be worsened by increased vascular tone.

- Assess for supine hypertension before initiating therapy and periodically during treatment. - Use caution in patients with cardiovascular disease, such as ischemic heart disease or heart failure. - Avoid in individuals with severe renal or hepatic impairment unless dose adjustments are made. - Monitor for urinary retention, especially in patients with prostate enlargement or bladder outlet obstruction. - Counsel patients to rise slowly from sitting or lying positions to reduce dizziness. - Advise against taking the medication within four hours of bedtime to minimize risk of nighttime hypertension.

Gutron may interact with other medicines that affect blood pressure, heart rate, or adrenergic pathways, requiring careful review of a patient’s medication list.

Avoid: - Concomitant use with other vasopressors or alpha‑adrenergic agonists (e.g., phenylephrine) that may cause excessive hypertension. - Monoamine oxidase inhibitors (MAOIs) due to potential additive pressor effects. - Tricyclic antidepressants that increase norepinephrine levels, raising the risk of hypertensive episodes.

Use with caution: - Diuretics, because they may enhance orthostatic hypotension when combined with Gutron. - Beta‑blockers, which can blunt compensatory tachycardia and affect blood pressure control. - Anticholinergic agents, as they may increase the likelihood of urinary retention.